ClinicalTrials.gg
CompletedNCT01044264Updated Jul 12, 2023Results posted

Clinical Study Between Two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel Formulations

An interventional study of 1% Clindamycin/5% Benzoyl Peroxide Topical Gel and Placebo in Acne Vulgaris, sponsored by Padagis LLC. Completed. Open to participants aged 12 Years to 40 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-07-12.

Sponsored by Padagis LLC · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
602
Allocation
Randomized
Ages
12 Years to 40 Years
Sex
All
01

Study summary

A randomized, double-blind, multiple-site, placebo-controlled, parallel-group clinical study conducted to evaluate the bioequivalence of two 1% Clindamycin/5% Benzoyl Peroxide Topical Gel formulations.

02

Conditions studied

  • Acne Vulgaris

Browse trials for

Keywords

  • Acne Vulgaris
  • bioequivalency
  • clindamycin
  • benzoyl peroxide
03

In context

Acne Vulgaris

795 studies on the registry are indexed under Acne Vulgaris; 96 are open to participants now.

This study's enrollment of 602 is above the median of 70 across 676 interventional studies indexed under Acne Vulgaris.

Browse Acne Vulgaris studies →

Lead sponsor

Padagis LLC is the lead sponsor of 37 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 40 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • healthy men or women, 12 years of age and older
  • willing to participate and sign a copy of the form
  • moderate to severe facial acne

Exclusion criteria

Exclusion Criteria:

  • history of allergy or to clindamycin or benzoyl peroxide
  • pregnant or lactating women
  • evidence of a disorder
  • receipt of any drugs as part of a research study within 30 days prior to study dosing
  • use of systemic, topical or facial products which may interfere with study
  • significant facial hair, tattoos, excessive facial scarring, active facial sunburn, or peeling due to sunburn
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
602 participants (actual)

Study arms

  • Active comparator
    1% Clindamycin/5% Benzoyl Peroxide Topical Gel

    Test product

    Drug: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel

  • Active comparator
    DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel

    Reference product

    Drug: 1% Clindamycin/5% Benzoyl Peroxide Topical Gel

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Drug1% Clindamycin/5% Benzoyl Peroxide Topical Gel

    Topical Gel

    Also known as: DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Reduction of Inflammatory Lesions

    The primary endpoint of the study was the mean percent reduction from baseline to week 11 in inflamed lesion count (papules and pustules).

    Time frame: Baseline and week 11

07

Results

Posted Dec 17, 2012

Participant flow

FIRST PATIENT ENROLLED: 12/11/2007 LAST PATIENT COMPLETED: 9/18/2008

Participant flow — Overall Study
Milestone1% Clindamycin/5% Benzoyl Peroxide Topical GelDUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical GelPlacebo
Started200202200
Completed110108108
Not completed909492

Outcome measures

PrimaryReduction of Inflammatory Lesions

The primary endpoint of the study was the mean percent reduction from baseline to week 11 in inflamed lesion count (papules and pustules).

Time frame:
Baseline and week 11
Reported as:
Number · percentage reduction of lesions
Reduction of Inflammatory Lesions
percentage reduction of lesions1% Clindamycin/5% Benzoyl Peroxide Topical GelDUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical GelPlacebo
Reduction of Inflammatory Lesions64.3963.1049.89
Statistical analysis
  • 1% Clindamycin/5% Benzoyl Peroxide Topical Gel vs DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel · Wilcoxon Rank Sum Test · Wilcoxon rank sum test: 100 · 90% CI 92.47 to 113.54

Adverse events

Collected over 11 week treatment period. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
1% Clindamycin/5% Benzoyl Peroxide Topical Gel——40/200 (20%)
DUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical Gel——35/202 (17.3%)
Placebo——28/200 (14%)
Most frequent serious events
Most frequent serious events
Event1% Clindamycin/5% Benzoyl Peroxide Topical GelDUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical GelPlacebo
Kidney CancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/2000/2020/200
HematuriaRenal and urinary disorders1/2000/2020/200
Mild Bipolar Conduct DisorderPsychiatric disorders0/2000/2021/200
Most frequent other events
Most frequent other events
Event1% Clindamycin/5% Benzoyl Peroxide Topical GelDUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical GelPlacebo
application site drynessSkin and subcutaneous tissue disorders25/20021/20221/200
headacheNervous system disorders3/2008/2023/200
NasopharyngitisEar and labyrinth disorders4/2003/2022/200
Application Site BurningSkin and subcutaneous tissue disorders4/2002/2021/200
InfluenzaInfections and infestations4/2001/2021/200

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)1% Clindamycin/5% Benzoyl Peroxide Topical GelDUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical GelPlaceboTotal
<=18 years117113113343
Between 18 and 65 years838987259
>=65 years0000
Age, Continuous
Age, Continuous(years)1% Clindamycin/5% Benzoyl Peroxide Topical GelDUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical GelPlaceboTotal
Mean19.2 ± 7.319.5 ± 7.120.1 ± 8.319.6 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)1% Clindamycin/5% Benzoyl Peroxide Topical GelDUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical GelPlaceboTotal
Female103101113317
Male9710187285
Region of Enrollment
Region of Enrollment(participants)1% Clindamycin/5% Benzoyl Peroxide Topical GelDUAC® 1% Clindamycin/5% Benzoyl Peroxide Topical GelPlaceboTotal
United States200202200602
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2007, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2012, 4 years 3 months after primary completion. A results delay was requested in Mar 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 4, 2010
First posted
Jan 7, 2010
Start
Dec 2007
Primary completionActual
Sep 2008
CompletionActual
Sep 2008
Results delay requested
Mar 15, 2012
Results first posted
Dec 17, 2012
Last update
Jul 12, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01044264
Lead sponsor
Padagis LLC
Responsible party
Sponsor
First posted
Jan 7, 2010
Start date
Dec 2007
Primary completion
Sep 2008
Completion
Sep 2008
Results posted
Dec 17, 2012
Last update
Jul 12, 2023

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion